Wisconsin Lawmakers Introduce 340B Anti-Discrimination Measure but Leave Out Most 340B Hospitals

Wisconsin Gov. Tony Evers (D) is pushing for passage of legislation to eliminate payer and pharmacy benefit manager (PBM) discrimination against health centers, critical access hospitals, Ryan White HIV/AIDS program grantees, and their contract pharmacies.

Wisconsin Gov. Tony Evers (D) is pushing for passage of a package of 13 “Less for Rx” bills to control prescription drug costs, including one to eliminate payer and pharmacy benefit manager (PBM) discrimination against certain 340B covered entities.

The

Read More »

Contrary to Reports, Judge in AstraZeneca Lawsuit Did Not Strike Down 340B Unlimited Contract Pharmacy, Court Clerk Says

U.S. Chief District Judge Leonard Stark did not rule that AstraZeneca is not required to deliver 340B discounts drugs to an unlimited number of contract pharmacies, the court clerk's office said today.

The clerk of the federal district court in Wilmington, Del., confirmed this morning that a judge did not rule that drug manufacturer AstraZeneca is not required to deliver 340B discounts drugs to an unlimited number of contract pharmacies. There were

Read More »

Insulin Manufacturers Colluded on 340B Contract Pharmacy After Joint Lobbying Push Failed, Lawsuit Alleges

Four insulin manufacturers conspired to deny 340B discounts on their products shipped to contract pharmacies after an effort to lobby the Trump administration failed, a lawsuit alleges.

CORRECTION Thursday, Aug. 5, 2021, 8:15 p.m.—Earlier today, we misdescribed Novo Nordisk’s 340B contract pharmacy policy. Beginning on Jan. 1, 2021, Novo Nordisk stopped facilitating bill to/ship to distribution of 340B product to hospital contract pharmacies. We incorrectly said Novo

Read More »

340B Report Publisher and CEO Says New Bipartisan 340B Bill is Win for Providers and Drug Industry

The PROTECT 340B solves "two of the most intractable challenges in the 340B program in one fell swoop," 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.

U.S. Reps. David McKinley (R-W.Va.) and Abigail Spanberger’s (D-Va.) bipartisan PROTECT 340B Act (H.R. 4390) can “resolve two of the most intractable challenges in the 340B program in one fell swoop” while satisfying both covered entities and drug manufacturers, 340B

Read More »

Biopharma Company Apellis Posts 340B Limited Distribution Notice

Apellis has posted a notice on HRSA's website informing 340B entities how they can get 340B pricing on the company's new product, Empaveli, which has a REMS.

Biopharmaceutical company Apellis has announced a limited distribution plan for Empaveli (pegcetacoplan), a newly approved treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, life-threatening blood disorder.

The U.S. Food and Drug Administration (FDA) approved Empaveli on

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Jennifer Lockwood, CEO/Founder, Ravin Consultants

Jennifer Lockwood

Q: Where did you grow up?

I grew up in Scranton and Mechanicsburg, Pennsylvania and regularly traveled from Pittsburgh to Philly. My mom was a registered nurse, and I would volunteer to assist her growing up.  Caring for her patients not only ignited my philanthropic passion but also illuminated the many bumps on their road to recovery. I

Read More »

Health Center Files 340B Contract Pharmacy Antitrust Suit Against Insulin Makers, Seeks Nationwide Class Action Certification

The reception area in Mosaic Health's Illion, N.Y., location. Mosaic accuses four insulin manufacturers in a new lawsuit of conspiring to raise prices for 340B entities that use contract pharmacies.

An upstate New York health center has sued the nation’s four major insulin manufacturers for allegedly conspiring to stop offering 340B pricing when covered entities use contract pharmacies.

Mosaic Health’s July 30 lawsuit claims that insulin manufacturers’ Sanofi, Eli

Read More »

Boehringer Ingelheim Halts 340B Pricing on Contract Pharmacy Drugs

Boehringer Ingelheim on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals use contract pharmacies.

Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.

BI this morning confirmed that it has begun denying 340B pricing

Read More »

Infrastructure Bill Excludes Spread-Pricing Language That 340B Entities Oppose

An infrastructure-spending bill nearing a vote in the U.S. Senate excludes Medicaid managed care “spread pricing” language that 340B entities have been fending off since 2019.

340B covered entities dodged a bullet Sunday when U.S. Senate negotiators released the text of a $550 billion bipartisan infrastructure-spending bill. It did not contain Medicaid managed care “spread pricing” language that entities have been fending off since 2019. Entities

Read More »

Young Firebrand Lawmaker Gets into Shouting Match with 340B Champion

U.S. Rep. Madison Cawthorn (R-N.C., left) and the staff of Rep. David McKinley (R-W.Va., right) allegedly got into "a back-and-forth" last week over Cawthorn's listing as a co-sponsor of 340B legislation that McKinley filed with Rep. Abigail Spanberger (D-Va.).

News organization Politico reports that U.S. Rep. Madison Cawthorn (R-N.C.) “got into a back-and-forth with” the staff of Rep. David McKinley (R-W.Va.) last week Thursday, July 29, over Cawthorn’s listing as a co-sponsor of legislation to protect 340B covered

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live